This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsInd-Swift（INDSWFTLTD）株式概要インド・スウィフト社は、インドで医薬製剤、最終製品、原薬、ハーブ製品を開発している。 詳細INDSWFTLTD ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績4/6財務の健全性0/6配当金0/6報酬株価収益率（ 0.3 x） Indian市場（ 23.9 x）を下回っています。過去1年間で収益は1891.7%増加しました リスク分析株式の流動性は非常に低い 意味のある時価総額がありません ( ₹850M )高いレベルの非現金収入 負債は営業キャッシュフローで十分にカバーされていない +1 さらなるリスクすべてのリスクチェックを見るINDSWFTLTD Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW486,402 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG486,402 investors already sharing narrativesYour Fair Value₹Current Price₹15.7676.9% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-4b8b2016201920222025202620282031Revenue ₹7.9bEarnings ₹4.3bAdvancedSet Fair ValueView all narrativesInd-Swift Limited 競合他社PhaarmasiaSymbol: BSE:523620Market cap: ₹634.8mAccretion PharmaceuticalsSymbol: NSEI:ACCPLMarket cap: ₹1.8bZenith DrugsSymbol: NSEI:ZENITHDRUGMarket cap: ₹874.6mAmwill Health CareSymbol: BSE:544353Market cap: ₹868.0m価格と性能株価の高値、安値、推移の概要Ind-Swift過去の株価現在の株価₹15.7652週高値₹34.7052週安値₹12.00ベータ-0.721ヶ月の変化0%3ヶ月変化6.13%1年変化-30.57%3年間の変化73.19%5年間の変化494.72%IPOからの変化-92.44%最新ニュースNew Risk • Aug 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Market cap is less than US$10m (₹850.4m market cap, or US$9.78m).お知らせ • Aug 09Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) Completed the acquisition of Ind-Swift Limited (BSE:524652).Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652) for INR 708 million on September 25, 2023. The above-mentioned Scheme shall be subject to the approval of the BSE Limited, National Stock Exchange of India Limited, Securities Exchange Board of India, National Company Law Tribunal, Shareholders and Creditors of both the Companies and other Specific Sectoral Regulator. The Board of Directors of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Ind-Swift Limited (BSE:524652) in their meeting held on September 25, 2023, has considered and approved the Scheme of Arrangement for Amalgamation of Ind Swift Limited with Ind Swift Laboratories Limited. The proceeds of the said sale shall be used primarily to repay its debt and to discharge other financial obligations. As of May 15, 2025, Company had filed Second motion Petition before the Hon’ble National Company Law Tribunal (NCLT), Chandigarh Bench-II for the approval of the Scheme of Arrangement for Amalgamation of Ind Swift Limited (“Transferor Company”) with Ind Swift Laboratories Limited (“Transferee Company”) (“Scheme”). The matter was listed for hearing today i.e. May 15, 2025 before the Hon’ble tribunal for discussion on reports submitted by statutory authorities and further approval of scheme by the Hon’ble NCLT Chandigarh Bench. As of July 8, 2025 both the companies have filed Form No. INC-28 with Registrar of Companies (ROC) today. 3Dimension Capital Services Limited and Ekadrisht Capital Private Limited acted as fairness provider to Ind-Swift Laboratories Limited and Ind-Swift Limited respectively. Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) Completed the acquisition of Ind-Swift Limited (BSE:524652) on August 8, 2025.New Risk • Aug 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹867.2m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Market cap is less than US$10m (₹867.2m market cap, or US$9.88m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.02b market cap, or US$11.9m).New Risk • Jun 26New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 93% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Minor Risk Market cap is less than US$100m (₹900.2m market cap, or US$10.5m).Reported Earnings • Jun 26Full year 2025 earnings released: EPS: ₹52.33 (vs ₹2.63 in FY 2024)Full year 2025 results: EPS: ₹52.33 (up from ₹2.63 in FY 2024). Revenue: ₹5.63b (up 12% from FY 2024). Net income: ₹2.83b (up ₹2.69b from FY 2024). Profit margin: 50% (up from 2.8% in FY 2024). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.最新情報をもっと見るRecent updatesNew Risk • Aug 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Market cap is less than US$10m (₹850.4m market cap, or US$9.78m).お知らせ • Aug 09Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) Completed the acquisition of Ind-Swift Limited (BSE:524652).Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652) for INR 708 million on September 25, 2023. The above-mentioned Scheme shall be subject to the approval of the BSE Limited, National Stock Exchange of India Limited, Securities Exchange Board of India, National Company Law Tribunal, Shareholders and Creditors of both the Companies and other Specific Sectoral Regulator. The Board of Directors of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Ind-Swift Limited (BSE:524652) in their meeting held on September 25, 2023, has considered and approved the Scheme of Arrangement for Amalgamation of Ind Swift Limited with Ind Swift Laboratories Limited. The proceeds of the said sale shall be used primarily to repay its debt and to discharge other financial obligations. As of May 15, 2025, Company had filed Second motion Petition before the Hon’ble National Company Law Tribunal (NCLT), Chandigarh Bench-II for the approval of the Scheme of Arrangement for Amalgamation of Ind Swift Limited (“Transferor Company”) with Ind Swift Laboratories Limited (“Transferee Company”) (“Scheme”). The matter was listed for hearing today i.e. May 15, 2025 before the Hon’ble tribunal for discussion on reports submitted by statutory authorities and further approval of scheme by the Hon’ble NCLT Chandigarh Bench. As of July 8, 2025 both the companies have filed Form No. INC-28 with Registrar of Companies (ROC) today. 3Dimension Capital Services Limited and Ekadrisht Capital Private Limited acted as fairness provider to Ind-Swift Laboratories Limited and Ind-Swift Limited respectively. Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) Completed the acquisition of Ind-Swift Limited (BSE:524652) on August 8, 2025.New Risk • Aug 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹867.2m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Market cap is less than US$10m (₹867.2m market cap, or US$9.88m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.02b market cap, or US$11.9m).New Risk • Jun 26New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 93% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Minor Risk Market cap is less than US$100m (₹900.2m market cap, or US$10.5m).Reported Earnings • Jun 26Full year 2025 earnings released: EPS: ₹52.33 (vs ₹2.63 in FY 2024)Full year 2025 results: EPS: ₹52.33 (up from ₹2.63 in FY 2024). Revenue: ₹5.63b (up 12% from FY 2024). Net income: ₹2.83b (up ₹2.69b from FY 2024). Profit margin: 50% (up from 2.8% in FY 2024). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.お知らせ • May 23Ind-Swift Limited to Report Q4, 2025 Results on May 30, 2025Ind-Swift Limited announced that they will report Q4, 2025 results on May 30, 2025お知らせ • Feb 20Ind-Swift Limited Appoints Anil Agrawal as Chief Operating OfficerInd-Swift Limited announced that Mr. Anil Agrawal, has been appointed as "Chief Operating Officer (COO)" of the Company,effective from 20 February, 2025. Mr. Anil Agrawal Is A Seasoned Professional with A Bachelor of Pharmacy Degree from Devi Ahilya Vishwavidyalaya, Indore, Mp. He Has A Rich and Diverse Experience of More Than 25 Years in Leading Pharmaceutical Operations At Some of the Most Reputed Organizations in the Industry. His Distinguished Career Includes Leadership Roles At Ranbaxy Laboratories Ltd, Dr. Reddy's Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Glaxosmithkline Pharmaceuticals Ltd, Zydus Cadila Healthcare Ltd, Alembic Pharmaceuticals Ltd, Par Formulations, and Sun Pharmaceutical Industries Ltd. His Extensive Expertise in Pharmaceutical Manufacturing, Operational Efficiencies, and Business Transformation Will Be Invaluable in Elevating the company's Formulation Business to New Heights.Reported Earnings • Feb 12Third quarter 2025 earnings released: ₹1.02 loss per share (vs ₹2.76 loss in 3Q 2024)Third quarter 2025 results: ₹1.02 loss per share (improved from ₹2.76 loss in 3Q 2024). Revenue: ₹1.20b (up 17% from 3Q 2024). Net loss: ₹55.0m (loss narrowed 63% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 07Ind-Swift Limited to Report Q3, 2025 Results on Feb 11, 2025Ind-Swift Limited announced that they will report Q3, 2025 results at 9:15 AM, Indian Standard Time on Feb 11, 2025New Risk • Feb 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹866.6m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₹6.6b). High level of non-cash earnings (53% accrual ratio). Market cap is less than US$10m (₹866.6m market cap, or US$9.90m).Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹22.21, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 58% over the past three years.Valuation Update With 7 Day Price Move • Dec 31Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹33.05, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 137% over the past three years.New Risk • Dec 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Negative equity (-₹6.6b). High level of non-cash earnings (53% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₹1.46b market cap, or US$17.2m).Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improves as stock rises 32%After last week's 32% share price gain to ₹27.13, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 123% over the past three years.Reported Earnings • Nov 18Second quarter 2025 earnings released: EPS: ₹0.76 (vs ₹1.98 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.76 (up from ₹1.98 loss in 2Q 2024). Revenue: ₹1.41b (up 22% from 2Q 2024). Net income: ₹41.1m (up ₹148.2m from 2Q 2024). Profit margin: 2.9% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 09Ind-Swift Limited to Report Q2, 2025 Results on Nov 14, 2024Ind-Swift Limited announced that they will report Q2, 2025 results on Nov 14, 2024Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹18.66, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Total returns to shareholders of 66% over the past three years.お知らせ • Sep 10Ind-Swift Limited Announces Resignation of Ginny Uppal as Company SecretaryInd-Swift Limited informed that CS Ginny Uppal (ACS- 53483) vide her letter dated September 6, 2024 has tendered her resignation from the post of Company Secretary & Compliance Officer and a Key Managerial Personnel of the Company to pursue carrier opportunity outside the company with effect from closing of business hours of September 6, 2024.お知らせ • Aug 14Ind-Swift Limited, Annual General Meeting, Sep 30, 2024Ind-Swift Limited, Annual General Meeting, Sep 30, 2024, at 13:30 Indian Standard Time.Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹5.21 (vs ₹0.44 in 1Q 2024)First quarter 2025 results: EPS: ₹5.21 (up from ₹0.44 in 1Q 2024). Revenue: ₹1.54b (up 3.5% from 1Q 2024). Net income: ₹282.4m (up ₹258.8m from 1Q 2024). Profit margin: 18% (up from 1.6% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.お知らせ • Aug 01Ind-Swift Limited to Report Q1, 2025 Results on Aug 13, 2024Ind-Swift Limited announced that they will report Q1, 2025 results on Aug 13, 2024Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹25.71, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 196% over the past three years.Valuation Update With 7 Day Price Move • Jul 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹23.05, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 356% over the past three years.New Risk • May 28New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 176% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-₹6.9b). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin). Market cap is less than US$100m (₹1.25b market cap, or US$15.0m).New Risk • May 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.5% Last year net profit margin: 6.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.3x net interest cover). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-₹6.9b). Minor Risks Profit margins are more than 30% lower than last year (2.5% net profit margin). Market cap is less than US$100m (₹1.15b market cap, or US$13.8m).Reported Earnings • May 17Full year 2024 earnings released: EPS: ₹2.63 (vs ₹4.81 in FY 2023)Full year 2024 results: EPS: ₹2.63 (down from ₹4.81 in FY 2023). Revenue: ₹5.60b (up 36% from FY 2023). Net income: ₹142.3m (down 45% from FY 2023). Profit margin: 2.5% (down from 6.3% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth.お知らせ • May 05Ind-Swift Limited to Report Q4, 2024 Results on May 14, 2024Ind-Swift Limited announced that they will report Q4, 2024 results on May 14, 2024Valuation Update With 7 Day Price Move • Apr 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹21.35, the stock trades at a trailing P/E ratio of 3.9x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 447% over the past three years.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₹23.70, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 451% over the past three years.Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹19.30, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 311% over the past three years.お知らせ • Mar 06Ind-Swift Limited Announces Cessation of Vinay Arora as an Independent DirectorInd-Swift Limited informed that Dr. Vinay Arora, has completed his second and final term of 5 (five) consecutive years as an Independent Director of the Company and consequently has ceased to be an Independent Director of the Company w.e.f. the close of business hours on March 6, 2024. Consequent to the Completion of the said second term of Dr. Vinay Arora, as an Independent Director of the Company, his membership and chairmanship in various committees of the Board also cease to exist.Valuation Update With 7 Day Price Move • Feb 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹20.80, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 420% over the past three years.Reported Earnings • Feb 16Third quarter 2024 earnings released: ₹2.76 loss per share (vs ₹0.19 loss in 3Q 2023)Third quarter 2024 results: ₹2.76 loss per share (further deteriorated from ₹0.19 loss in 3Q 2023). Revenue: ₹1.05b (down 1.3% from 3Q 2023). Net loss: ₹149.7m (loss widened ₹139.3m from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 63% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹21.35, the stock trades at a trailing P/E ratio of 2.6x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 391% over the past three years.お知らせ • Jan 30Ind-Swift Limited to Report Q3, 2024 Results on Feb 13, 2024Ind-Swift Limited announced that they will report Q3, 2024 results on Feb 13, 2024Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹18.80, the stock trades at a trailing P/E ratio of 2.3x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 596% over the past three years.Reported Earnings • Nov 10Second quarter 2024 earnings released: ₹1.98 loss per share (vs ₹1.96 loss in 2Q 2023)Second quarter 2024 results: ₹1.98 loss per share (further deteriorated from ₹1.96 loss in 2Q 2023). Revenue: ₹1.19b (up 15% from 2Q 2023). Net loss: ₹107.1m (loss widened 1.1% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Oct 31Ind-Swift Limited to Report Q2, 2024 Results on Nov 09, 2023Ind-Swift Limited announced that they will report Q2, 2024 results on Nov 09, 2023New Risk • Oct 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹806.5m (US$9.69m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Negative equity (-₹7.0b). Market cap is less than US$10m (₹806.5m market cap, or US$9.69m). Minor Risk Large one-off items impacting financial results.Valuation Update With 7 Day Price Move • Oct 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹16.80, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 360% over the past three years.お知らせ • Sep 27Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652) on September 25, 2023. The above-mentioned Scheme shall be subject to the approval of the BSE Limited, National Stock Exchange of India Limited, Securities Exchange Board of India, National Company Law Tribunal, Shareholders and Creditors of both the Companies and other Specific Sectoral Regulator. The Board of Directors of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Ind-Swift Limited (BSE:524652) in their meeting held on September 25, 2023, has considered and approved the Scheme of Arrangement for Amalgamation of Ind Swift Limited with Ind Swift Laboratories Limited. The proceeds of the said sale shall be used primarily to repay its debt and to discharge other financial obligations.お知らせ • Sep 01Ind-Swift Limited, Annual General Meeting, Sep 30, 2023Ind-Swift Limited, Annual General Meeting, Sep 30, 2023, at 13:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹16.65, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 397% over the past three years.Reported Earnings • Aug 11First quarter 2024 earnings released: EPS: ₹0.44 (vs ₹2.85 loss in 1Q 2023)First quarter 2024 results: EPS: ₹0.44 (up from ₹2.85 loss in 1Q 2023). Revenue: ₹1.54b (up 63% from 1Q 2023). Net income: ₹23.6m (up ₹178.0m from 1Q 2023). Profit margin: 1.5% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 01Ind-Swift Limited to Report Q1, 2024 Results on Aug 10, 2023Ind-Swift Limited announced that they will report Q1, 2024 results on Aug 10, 2023Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹12.80, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 282% over the past three years.Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹10.70, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 224% over the past three years.Reported Earnings • Jun 02Full year 2023 earnings released: EPS: ₹4.81 (vs ₹3.70 loss in FY 2022)Full year 2023 results: EPS: ₹4.81 (up from ₹3.70 loss in FY 2022). Revenue: ₹4.23b (up 5.2% from FY 2022). Net income: ₹260.4m (up ₹460.6m from FY 2022). Profit margin: 6.2% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • May 17Ind-Swift Limited to Report Q4, 2023 Results on May 30, 2023Ind-Swift Limited announced that they will report Q4, 2023 results on May 30, 2023分析記事 • Apr 18Ind-Swift Limited (NSE:INDSWFTLTD) Stock Catapults 28% Though Its Price And Business Still Lag The IndustryInd-Swift Limited ( NSE:INDSWFTLTD ) shareholders are no doubt pleased to see that the share price has bounced 28% in...Reported Earnings • Feb 14Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: ₹1.10b (up 5.2% from 3Q 2022). Net loss: ₹10.3m (loss narrowed 83% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.お知らせ • Jan 29Ind-Swift Limited to Report Q3, 2023 Results on Feb 13, 2023Ind-Swift Limited announced that they will report Q3, 2023 results on Feb 13, 2023Reported Earnings • Nov 19Second quarter 2023 earnings released: ₹1.96 loss per share (vs ₹0.91 loss in 2Q 2022)Second quarter 2023 results: ₹1.96 loss per share (further deteriorated from ₹0.91 loss in 2Q 2022). Revenue: ₹1.05b (up 7.6% from 2Q 2022). Net loss: ₹105.9m (loss widened 115% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 40% per year, which means it is well ahead of earnings.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Non-Executive Independent Director Bhupinder Singh was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 11First quarter 2023 earnings released: ₹2.85 loss per share (vs ₹0.66 loss in 1Q 2022)First quarter 2023 results: ₹2.85 loss per share (down from ₹0.66 loss in 1Q 2022). Revenue: ₹961.8m (up 6.4% from 1Q 2022). Net loss: ₹154.4m (loss widened 333% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings.Reported Earnings • Jun 02Full year 2022 earnings released: ₹3.70 loss per share (vs ₹5.51 loss in FY 2021)Full year 2022 results: ₹3.70 loss per share (up from ₹5.51 loss in FY 2021). Revenue: ₹4.21b (up 17% from FY 2021). Net loss: ₹200.2m (loss narrowed 33% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 8 highly experienced directors. 5 independent directors (6 non-independent directors). Independent Director Jagvir Ahluwalia was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹1.11 loss per share (down from ₹0.22 loss in 3Q 2021). Revenue: ₹1.07b (up 1.0% from 3Q 2021). Net loss: ₹60.4m (loss widened 407% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 18First quarter 2022 earnings released: ₹0.66 loss per share (vs ₹1.64 loss in 1Q 2021)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: ₹964.7m (up 51% from 1Q 2021). Net loss: ₹35.7m (loss narrowed 60% from 1Q 2021).Reported Earnings • Jul 04Full year 2021 earnings released: ₹5.50 loss per share (vs ₹3.53 loss in FY 2020)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: ₹3.65b (up 8.4% from FY 2020). Net loss: ₹298.2m (loss widened 56% from FY 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.分析記事 • Feb 17How Much Is Ind-Swift Limited (NSE:INDSWFTLTD) Paying Its CEO?Gopal Munjal became the CEO of Ind-Swift Limited ( NSE:INDSWFTLTD ) in 2008, and we think it's a good time to look at...Reported Earnings • Feb 17Third quarter 2021 earnings released: ₹0.22 loss per share (vs ₹2.18 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: ₹1.06b (up 6.6% from 3Q 2020). Net loss: ₹11.9m (loss narrowed 90% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 12New 90-day high: ₹4.40The company is up 22% from its price of ₹3.60 on 12 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.Is New 90 Day High Low • Nov 14New 90-day low: ₹2.75The company is down 8.0% from its price of ₹3.00 on 14 August 2020. The Indian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.Reported Earnings • Nov 12Second quarter 2021 earnings released: ₹0.42 loss per shareThe company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: ₹983.8m (down 1.1% from 2Q 2020). Net loss: ₹22.9m (loss narrowed 81% from 2Q 2020).株主還元INDSWFTLTDIN PharmaceuticalsIN 市場7D0%0.8%0.8%1Y-30.6%11.6%-1.2%株主還元を見る業界別リターン: INDSWFTLTD過去 1 年間で11.6 % の収益を上げたIndian Pharmaceuticals業界を下回りました。リターン対市場: INDSWFTLTDは、過去 1 年間で-1.2 % のリターンを上げたIndian市場を下回りました。価格変動Is INDSWFTLTD's price volatile compared to industry and market?INDSWFTLTD volatilityINDSWFTLTD Average Weekly Movementn/aPharmaceuticals Industry Average Movement6.3%Market Average Movement6.1%10% most volatile stocks in IN Market9.1%10% least volatile stocks in IN Market3.8%安定した株価: INDSWFTLTDの株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のINDSWFTLTDのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト19831,054Gopal Munjalwww.indswiftltd.comInd-Swift Limited は、インドで医薬品製剤、完成品製剤、原薬、ハーブ製品を開発している。Zoxiclav、Glypar、Olmiswif、Telhim、Ozodom-DSR、Cefextil-O、Swiclo-Sp、Swifix-O、Swicix 200、Stemin、Stemin Forteの名称で、耳鼻咽喉科、歯科、抗感染症、心臓糖尿病、整形外科など様々な治療分野の医薬品を提供している。また、婦人科、小児科、皮膚科を含む様々な治療用の医薬品やその他のジェネリック医薬品をAnin、Suprox、Cozy、Distone、Oliadeの名称で提供している。さらに、抗生物質、風邪薬、栄養補助食品、下痢止め、抗マラリア薬、抗うつ薬、心臓病学、糖尿病学、抗うつ薬、抗アレルギー薬、抗感染症薬、神経学、腫瘍学も提供している。インド・スウィフト社は、アーユルヴェーダ製品、受託研究・製造サービスを提供している。同社は製品を輸出し、ヨーロッパ、オーストラリア、カナダ、南アフリカ、ロシアにライセンス供与している。スウィフト社は1983年に設立され、インドのチャンディーガルに本社を置いている。もっと見るInd-Swift Limited 基礎のまとめInd-Swift の収益と売上を時価総額と比較するとどうか。INDSWFTLTD 基礎統計学時価総額₹850.39m収益（TTM）₹2.83b売上高(TTM)₹5.15b0.3xPER（株価収益率0.2xP/SレシオINDSWFTLTD は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計INDSWFTLTD 損益計算書（TTM）収益₹5.15b売上原価₹2.60b売上総利益₹2.55bその他の費用-₹283.97m収益₹2.83b直近の収益報告Mar 31, 2025次回決算日該当なし一株当たり利益（EPS）52.33グロス・マージン49.50%純利益率55.01%有利子負債／自己資本比率-217.2%INDSWFTLTD の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/11/10 22:06終値2025/08/13 00:00収益2025/03/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ind-Swift Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Aug 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Market cap is less than US$10m (₹850.4m market cap, or US$9.78m).
お知らせ • Aug 09Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) Completed the acquisition of Ind-Swift Limited (BSE:524652).Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652) for INR 708 million on September 25, 2023. The above-mentioned Scheme shall be subject to the approval of the BSE Limited, National Stock Exchange of India Limited, Securities Exchange Board of India, National Company Law Tribunal, Shareholders and Creditors of both the Companies and other Specific Sectoral Regulator. The Board of Directors of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Ind-Swift Limited (BSE:524652) in their meeting held on September 25, 2023, has considered and approved the Scheme of Arrangement for Amalgamation of Ind Swift Limited with Ind Swift Laboratories Limited. The proceeds of the said sale shall be used primarily to repay its debt and to discharge other financial obligations. As of May 15, 2025, Company had filed Second motion Petition before the Hon’ble National Company Law Tribunal (NCLT), Chandigarh Bench-II for the approval of the Scheme of Arrangement for Amalgamation of Ind Swift Limited (“Transferor Company”) with Ind Swift Laboratories Limited (“Transferee Company”) (“Scheme”). The matter was listed for hearing today i.e. May 15, 2025 before the Hon’ble tribunal for discussion on reports submitted by statutory authorities and further approval of scheme by the Hon’ble NCLT Chandigarh Bench. As of July 8, 2025 both the companies have filed Form No. INC-28 with Registrar of Companies (ROC) today. 3Dimension Capital Services Limited and Ekadrisht Capital Private Limited acted as fairness provider to Ind-Swift Laboratories Limited and Ind-Swift Limited respectively. Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) Completed the acquisition of Ind-Swift Limited (BSE:524652) on August 8, 2025.
New Risk • Aug 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹867.2m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Market cap is less than US$10m (₹867.2m market cap, or US$9.88m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.02b market cap, or US$11.9m).
New Risk • Jun 26New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 93% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Minor Risk Market cap is less than US$100m (₹900.2m market cap, or US$10.5m).
Reported Earnings • Jun 26Full year 2025 earnings released: EPS: ₹52.33 (vs ₹2.63 in FY 2024)Full year 2025 results: EPS: ₹52.33 (up from ₹2.63 in FY 2024). Revenue: ₹5.63b (up 12% from FY 2024). Net income: ₹2.83b (up ₹2.69b from FY 2024). Profit margin: 50% (up from 2.8% in FY 2024). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
New Risk • Aug 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.0% average weekly change). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Market cap is less than US$10m (₹850.4m market cap, or US$9.78m).
お知らせ • Aug 09Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) Completed the acquisition of Ind-Swift Limited (BSE:524652).Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652) for INR 708 million on September 25, 2023. The above-mentioned Scheme shall be subject to the approval of the BSE Limited, National Stock Exchange of India Limited, Securities Exchange Board of India, National Company Law Tribunal, Shareholders and Creditors of both the Companies and other Specific Sectoral Regulator. The Board of Directors of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Ind-Swift Limited (BSE:524652) in their meeting held on September 25, 2023, has considered and approved the Scheme of Arrangement for Amalgamation of Ind Swift Limited with Ind Swift Laboratories Limited. The proceeds of the said sale shall be used primarily to repay its debt and to discharge other financial obligations. As of May 15, 2025, Company had filed Second motion Petition before the Hon’ble National Company Law Tribunal (NCLT), Chandigarh Bench-II for the approval of the Scheme of Arrangement for Amalgamation of Ind Swift Limited (“Transferor Company”) with Ind Swift Laboratories Limited (“Transferee Company”) (“Scheme”). The matter was listed for hearing today i.e. May 15, 2025 before the Hon’ble tribunal for discussion on reports submitted by statutory authorities and further approval of scheme by the Hon’ble NCLT Chandigarh Bench. As of July 8, 2025 both the companies have filed Form No. INC-28 with Registrar of Companies (ROC) today. 3Dimension Capital Services Limited and Ekadrisht Capital Private Limited acted as fairness provider to Ind-Swift Laboratories Limited and Ind-Swift Limited respectively. Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) Completed the acquisition of Ind-Swift Limited (BSE:524652) on August 8, 2025.
New Risk • Aug 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹867.2m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Market cap is less than US$10m (₹867.2m market cap, or US$9.88m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
New Risk • Jul 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.8% operating cash flow to total debt). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹1.02b market cap, or US$11.9m).
New Risk • Jun 26New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 93% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Negative equity (-₹4.0b). High level of non-cash earnings (93% accrual ratio). Minor Risk Market cap is less than US$100m (₹900.2m market cap, or US$10.5m).
Reported Earnings • Jun 26Full year 2025 earnings released: EPS: ₹52.33 (vs ₹2.63 in FY 2024)Full year 2025 results: EPS: ₹52.33 (up from ₹2.63 in FY 2024). Revenue: ₹5.63b (up 12% from FY 2024). Net income: ₹2.83b (up ₹2.69b from FY 2024). Profit margin: 50% (up from 2.8% in FY 2024). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
お知らせ • May 23Ind-Swift Limited to Report Q4, 2025 Results on May 30, 2025Ind-Swift Limited announced that they will report Q4, 2025 results on May 30, 2025
お知らせ • Feb 20Ind-Swift Limited Appoints Anil Agrawal as Chief Operating OfficerInd-Swift Limited announced that Mr. Anil Agrawal, has been appointed as "Chief Operating Officer (COO)" of the Company,effective from 20 February, 2025. Mr. Anil Agrawal Is A Seasoned Professional with A Bachelor of Pharmacy Degree from Devi Ahilya Vishwavidyalaya, Indore, Mp. He Has A Rich and Diverse Experience of More Than 25 Years in Leading Pharmaceutical Operations At Some of the Most Reputed Organizations in the Industry. His Distinguished Career Includes Leadership Roles At Ranbaxy Laboratories Ltd, Dr. Reddy's Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Glaxosmithkline Pharmaceuticals Ltd, Zydus Cadila Healthcare Ltd, Alembic Pharmaceuticals Ltd, Par Formulations, and Sun Pharmaceutical Industries Ltd. His Extensive Expertise in Pharmaceutical Manufacturing, Operational Efficiencies, and Business Transformation Will Be Invaluable in Elevating the company's Formulation Business to New Heights.
Reported Earnings • Feb 12Third quarter 2025 earnings released: ₹1.02 loss per share (vs ₹2.76 loss in 3Q 2024)Third quarter 2025 results: ₹1.02 loss per share (improved from ₹2.76 loss in 3Q 2024). Revenue: ₹1.20b (up 17% from 3Q 2024). Net loss: ₹55.0m (loss narrowed 63% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 07Ind-Swift Limited to Report Q3, 2025 Results on Feb 11, 2025Ind-Swift Limited announced that they will report Q3, 2025 results at 9:15 AM, Indian Standard Time on Feb 11, 2025
New Risk • Feb 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹866.6m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-₹6.6b). High level of non-cash earnings (53% accrual ratio). Market cap is less than US$10m (₹866.6m market cap, or US$9.90m).
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹22.21, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 58% over the past three years.
Valuation Update With 7 Day Price Move • Dec 31Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹33.05, the stock trades at a trailing P/E ratio of 3.2x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 137% over the past three years.
New Risk • Dec 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Negative equity (-₹6.6b). High level of non-cash earnings (53% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₹1.46b market cap, or US$17.2m).
Valuation Update With 7 Day Price Move • Dec 06Investor sentiment improves as stock rises 32%After last week's 32% share price gain to ₹27.13, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 123% over the past three years.
Reported Earnings • Nov 18Second quarter 2025 earnings released: EPS: ₹0.76 (vs ₹1.98 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹0.76 (up from ₹1.98 loss in 2Q 2024). Revenue: ₹1.41b (up 22% from 2Q 2024). Net income: ₹41.1m (up ₹148.2m from 2Q 2024). Profit margin: 2.9% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 09Ind-Swift Limited to Report Q2, 2025 Results on Nov 14, 2024Ind-Swift Limited announced that they will report Q2, 2025 results on Nov 14, 2024
Valuation Update With 7 Day Price Move • Oct 25Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹18.66, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Total returns to shareholders of 66% over the past three years.
お知らせ • Sep 10Ind-Swift Limited Announces Resignation of Ginny Uppal as Company SecretaryInd-Swift Limited informed that CS Ginny Uppal (ACS- 53483) vide her letter dated September 6, 2024 has tendered her resignation from the post of Company Secretary & Compliance Officer and a Key Managerial Personnel of the Company to pursue carrier opportunity outside the company with effect from closing of business hours of September 6, 2024.
お知らせ • Aug 14Ind-Swift Limited, Annual General Meeting, Sep 30, 2024Ind-Swift Limited, Annual General Meeting, Sep 30, 2024, at 13:30 Indian Standard Time.
Reported Earnings • Aug 14First quarter 2025 earnings released: EPS: ₹5.21 (vs ₹0.44 in 1Q 2024)First quarter 2025 results: EPS: ₹5.21 (up from ₹0.44 in 1Q 2024). Revenue: ₹1.54b (up 3.5% from 1Q 2024). Net income: ₹282.4m (up ₹258.8m from 1Q 2024). Profit margin: 18% (up from 1.6% in 1Q 2024). Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.
お知らせ • Aug 01Ind-Swift Limited to Report Q1, 2025 Results on Aug 13, 2024Ind-Swift Limited announced that they will report Q1, 2025 results on Aug 13, 2024
Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹25.71, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 196% over the past three years.
Valuation Update With 7 Day Price Move • Jul 17Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹23.05, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 356% over the past three years.
New Risk • May 28New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 176% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-₹6.9b). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.8% net profit margin). Market cap is less than US$100m (₹1.25b market cap, or US$15.0m).
New Risk • May 17New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.5% Last year net profit margin: 6.3% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.3x net interest cover). Share price has been highly volatile over the past 3 months (13% average weekly change). Negative equity (-₹6.9b). Minor Risks Profit margins are more than 30% lower than last year (2.5% net profit margin). Market cap is less than US$100m (₹1.15b market cap, or US$13.8m).
Reported Earnings • May 17Full year 2024 earnings released: EPS: ₹2.63 (vs ₹4.81 in FY 2023)Full year 2024 results: EPS: ₹2.63 (down from ₹4.81 in FY 2023). Revenue: ₹5.60b (up 36% from FY 2023). Net income: ₹142.3m (down 45% from FY 2023). Profit margin: 2.5% (down from 6.3% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 58% per year, which means it is significantly lagging earnings growth.
お知らせ • May 05Ind-Swift Limited to Report Q4, 2024 Results on May 14, 2024Ind-Swift Limited announced that they will report Q4, 2024 results on May 14, 2024
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹21.35, the stock trades at a trailing P/E ratio of 3.9x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 447% over the past three years.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₹23.70, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 451% over the past three years.
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 23%After last week's 23% share price gain to ₹19.30, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 311% over the past three years.
お知らせ • Mar 06Ind-Swift Limited Announces Cessation of Vinay Arora as an Independent DirectorInd-Swift Limited informed that Dr. Vinay Arora, has completed his second and final term of 5 (five) consecutive years as an Independent Director of the Company and consequently has ceased to be an Independent Director of the Company w.e.f. the close of business hours on March 6, 2024. Consequent to the Completion of the said second term of Dr. Vinay Arora, as an Independent Director of the Company, his membership and chairmanship in various committees of the Board also cease to exist.
Valuation Update With 7 Day Price Move • Feb 29Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹20.80, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 420% over the past three years.
Reported Earnings • Feb 16Third quarter 2024 earnings released: ₹2.76 loss per share (vs ₹0.19 loss in 3Q 2023)Third quarter 2024 results: ₹2.76 loss per share (further deteriorated from ₹0.19 loss in 3Q 2023). Revenue: ₹1.05b (down 1.3% from 3Q 2023). Net loss: ₹149.7m (loss widened ₹139.3m from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 63% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹21.35, the stock trades at a trailing P/E ratio of 2.6x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 391% over the past three years.
お知らせ • Jan 30Ind-Swift Limited to Report Q3, 2024 Results on Feb 13, 2024Ind-Swift Limited announced that they will report Q3, 2024 results on Feb 13, 2024
Valuation Update With 7 Day Price Move • Nov 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹18.80, the stock trades at a trailing P/E ratio of 2.3x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 596% over the past three years.
Reported Earnings • Nov 10Second quarter 2024 earnings released: ₹1.98 loss per share (vs ₹1.96 loss in 2Q 2023)Second quarter 2024 results: ₹1.98 loss per share (further deteriorated from ₹1.96 loss in 2Q 2023). Revenue: ₹1.19b (up 15% from 2Q 2023). Net loss: ₹107.1m (loss widened 1.1% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Oct 31Ind-Swift Limited to Report Q2, 2024 Results on Nov 09, 2023Ind-Swift Limited announced that they will report Q2, 2024 results on Nov 09, 2023
New Risk • Oct 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹806.5m (US$9.69m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Negative equity (-₹7.0b). Market cap is less than US$10m (₹806.5m market cap, or US$9.69m). Minor Risk Large one-off items impacting financial results.
Valuation Update With 7 Day Price Move • Oct 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹16.80, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 360% over the past three years.
お知らせ • Sep 27Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652) on September 25, 2023. The above-mentioned Scheme shall be subject to the approval of the BSE Limited, National Stock Exchange of India Limited, Securities Exchange Board of India, National Company Law Tribunal, Shareholders and Creditors of both the Companies and other Specific Sectoral Regulator. The Board of Directors of Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) and Ind-Swift Limited (BSE:524652) in their meeting held on September 25, 2023, has considered and approved the Scheme of Arrangement for Amalgamation of Ind Swift Limited with Ind Swift Laboratories Limited. The proceeds of the said sale shall be used primarily to repay its debt and to discharge other financial obligations.
お知らせ • Sep 01Ind-Swift Limited, Annual General Meeting, Sep 30, 2023Ind-Swift Limited, Annual General Meeting, Sep 30, 2023, at 13:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Aug 21Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹16.65, the stock trades at a trailing P/E ratio of 2.1x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 397% over the past three years.
Reported Earnings • Aug 11First quarter 2024 earnings released: EPS: ₹0.44 (vs ₹2.85 loss in 1Q 2023)First quarter 2024 results: EPS: ₹0.44 (up from ₹2.85 loss in 1Q 2023). Revenue: ₹1.54b (up 63% from 1Q 2023). Net income: ₹23.6m (up ₹178.0m from 1Q 2023). Profit margin: 1.5% (up from net loss in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 01Ind-Swift Limited to Report Q1, 2024 Results on Aug 10, 2023Ind-Swift Limited announced that they will report Q1, 2024 results on Aug 10, 2023
Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹12.80, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 282% over the past three years.
Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹10.70, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 224% over the past three years.
Reported Earnings • Jun 02Full year 2023 earnings released: EPS: ₹4.81 (vs ₹3.70 loss in FY 2022)Full year 2023 results: EPS: ₹4.81 (up from ₹3.70 loss in FY 2022). Revenue: ₹4.23b (up 5.2% from FY 2022). Net income: ₹260.4m (up ₹460.6m from FY 2022). Profit margin: 6.2% (up from net loss in FY 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 63% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • May 17Ind-Swift Limited to Report Q4, 2023 Results on May 30, 2023Ind-Swift Limited announced that they will report Q4, 2023 results on May 30, 2023
分析記事 • Apr 18Ind-Swift Limited (NSE:INDSWFTLTD) Stock Catapults 28% Though Its Price And Business Still Lag The IndustryInd-Swift Limited ( NSE:INDSWFTLTD ) shareholders are no doubt pleased to see that the share price has bounced 28% in...
Reported Earnings • Feb 14Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: ₹1.10b (up 5.2% from 3Q 2022). Net loss: ₹10.3m (loss narrowed 83% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.
お知らせ • Jan 29Ind-Swift Limited to Report Q3, 2023 Results on Feb 13, 2023Ind-Swift Limited announced that they will report Q3, 2023 results on Feb 13, 2023
Reported Earnings • Nov 19Second quarter 2023 earnings released: ₹1.96 loss per share (vs ₹0.91 loss in 2Q 2022)Second quarter 2023 results: ₹1.96 loss per share (further deteriorated from ₹0.91 loss in 2Q 2022). Revenue: ₹1.05b (up 7.6% from 2Q 2022). Net loss: ₹105.9m (loss widened 115% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 40% per year, which means it is well ahead of earnings.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. Non-Executive Independent Director Bhupinder Singh was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 11First quarter 2023 earnings released: ₹2.85 loss per share (vs ₹0.66 loss in 1Q 2022)First quarter 2023 results: ₹2.85 loss per share (down from ₹0.66 loss in 1Q 2022). Revenue: ₹961.8m (up 6.4% from 1Q 2022). Net loss: ₹154.4m (loss widened 333% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings.
Reported Earnings • Jun 02Full year 2022 earnings released: ₹3.70 loss per share (vs ₹5.51 loss in FY 2021)Full year 2022 results: ₹3.70 loss per share (up from ₹5.51 loss in FY 2021). Revenue: ₹4.21b (up 17% from FY 2021). Net loss: ₹200.2m (loss narrowed 33% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 8 highly experienced directors. 5 independent directors (6 non-independent directors). Independent Director Jagvir Ahluwalia was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 17Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: ₹1.11 loss per share (down from ₹0.22 loss in 3Q 2021). Revenue: ₹1.07b (up 1.0% from 3Q 2021). Net loss: ₹60.4m (loss widened 407% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 18First quarter 2022 earnings released: ₹0.66 loss per share (vs ₹1.64 loss in 1Q 2021)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2022 results: Revenue: ₹964.7m (up 51% from 1Q 2021). Net loss: ₹35.7m (loss narrowed 60% from 1Q 2021).
Reported Earnings • Jul 04Full year 2021 earnings released: ₹5.50 loss per share (vs ₹3.53 loss in FY 2020)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: ₹3.65b (up 8.4% from FY 2020). Net loss: ₹298.2m (loss widened 56% from FY 2020). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
分析記事 • Feb 17How Much Is Ind-Swift Limited (NSE:INDSWFTLTD) Paying Its CEO?Gopal Munjal became the CEO of Ind-Swift Limited ( NSE:INDSWFTLTD ) in 2008, and we think it's a good time to look at...
Reported Earnings • Feb 17Third quarter 2021 earnings released: ₹0.22 loss per share (vs ₹2.18 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: ₹1.06b (up 6.6% from 3Q 2020). Net loss: ₹11.9m (loss narrowed 90% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 12New 90-day high: ₹4.40The company is up 22% from its price of ₹3.60 on 12 October 2020. The Indian market is up 24% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Nov 14New 90-day low: ₹2.75The company is down 8.0% from its price of ₹3.00 on 14 August 2020. The Indian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.
Reported Earnings • Nov 12Second quarter 2021 earnings released: ₹0.42 loss per shareThe company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: ₹983.8m (down 1.1% from 2Q 2020). Net loss: ₹22.9m (loss narrowed 81% from 2Q 2020).
